Tyra Biosciences, Inc.
TYRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001863127
In the last 90 days, Tyra Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 168 institutions reported holding it in 13F filings for Q2 2026, worth $2.22B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $1.38B
- Insider buysLast 90 days, $20.0K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +6 vs. previous quarter
- 168
- 13F valueReported value at the end of Q2 2026
- $2.22B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$119.9M
- No comparable prior period
- Free cash flow, FY2025
- -$95.3M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 9.90M
- Shares sold short
- Change
- +406.0K
- +4.3% vs. previous
- Days to cover
- 15.28
- At average daily volume
Superinvestors holding TYRA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TYRA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Tyra Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:31 PM ET | Sep 15 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +9.08M | $22.03 | +$200.0M | –11.6M after | Derivative |
| Sep 11, 2026 (view filing)4:30 PM ET | Sep 9 | 2 days | Verjee RehanDirector | PPurchase | +971.89 | $20.58 | +$20.0K | New position971.89 after | |
| Mar 27, 2026 (view filing) | Mar 25 | 2 days | Kaplan GillaDirector | SSale | −14.3K | $36.97 | −$528.5K | −33.6%28.2K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Bensen DanielChief Discovery Officer | SSale | −8.00K | $32.87 | −$263.0K | −5.2%147.0K after | 2 lots10b5-1 |
| Jan 20, 2026 (view filing) | Jan 12 | 8 daysLate | Bensen DanielChief Discovery Officer | SSale | −8.00K | $28.52 | −$228.2K | −4.9%155.0K after | 2 lots10b5-1 |
| Dec 19, 2025 (view filing) | Dec 19 | Same day | More Robert JDirector | SSale | −10.0K | $25.00 | −$250.0K | −0.3%3.82M after | 10b5-1 |
| Dec 16, 2025 (view filing) | Dec 12 | 4 days | Bensen DanielChief Discovery Officer | SSale | −8.00K | $22.64 | −$181.1K | −4.7%163.0K after | 10b5-1 |
| Nov 25, 2025 (view filing) | Nov 21 | 4 days | More Robert JDirector | SSale | −246.9K | $20.25 | −$5.00M | −6.1%3.83M after | 10b5-1 |
| Nov 19, 2025 (view filing) | Nov 18-19 | 1 day | Bensen DanielChief Operating Officer | SSale | −125.6K | $16.17 | −$2.03M | −42.3%171.0K after | 2 lots10b5-1 |
| Nov 17, 2025 (view filing) | Nov 13-17 | 4 days | Bensen DanielChief Operating Officer | SSale | −131.4K | $16.04 | −$2.11M | −30.7%296.6K after | 4 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 168 holdersThe largest institutional positions in Tyra Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,198,625 | $389.6M | 3.39% | 00.0% | Unchanged |
| FMR LLC | 8,920,513 | $284.9M | 0.01% | +1,172,865+15.1% | Added |
| Jupiter Topco LLC | 4,352,448 | $139.2M | 0.06% | +4,352,448 | New |
| Alta Partners Management Company, L.P. | 3,823,425 | $122.1M | 95.92% | 00.0% | Unchanged |
| Nextech Invest, Ltd. | 3,553,585 | $113.5M | 5.39% | −502,276−12.4% | Reduced |
| TCG Crossover Management, LLC | 3,248,980 | $103.8M | 2.49% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,031,972 | $96.8M | 0.00% | +814,043+36.7% | Added |
| Price T Rowe Associates Inc | 2,782,567 | $88.9M | 0.01% | +1,796,506+182.2% | Added |
| State Street Corp | 2,140,368 | $68.4M | 0.00% | +924,290+76.0% | Added |
| Commodore Capital LP | 1,875,000 | $59.9M | 3.57% | −600,000−24.2% | Reduced |
Holders of 5% or more of TYRA
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Tyra Biosciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 19.90%14.1M shares | −1.30 ppfrom 21.20% | Sep 27, 20218 filings | Sep 17, 2026 | SEC |
| FMR LLC | 13G | 14.40%7.75M shares | +11.20 ppfrom 3.20% | Feb 9, 20227 filings | Apr 7, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 7.20%3.89M shares | +1.80 ppfrom 5.40% | May 14, 20253 filings | May 15, 2026 | SEC |
| Farallon Capital Partners, L.P. | 13G/A | 6.60%3.58M shares | +1.00 ppfrom 5.60% | Feb 20, 20262 filings | May 12, 2026 | SEC |
| Biotechnology Value Fund L P | 13G | 6.10%4.22M shares | +2.10 ppfrom 4.00% | Mar 24, 20226 filings | Sep 21, 2026 | SEC |